Phase II of neoadjuvant pembrolizumab and epacadostat in patients with muscle-invasive urothelial bladder cancer: An open label, multicenter, single-arm study

Trial Profile

Phase II of neoadjuvant pembrolizumab and epacadostat in patients with muscle-invasive urothelial bladder cancer: An open label, multicenter, single-arm study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms PECULIAR
  • Most Recent Events

    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 16 Mar 2018 New trial record
    • 16 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top